期刊文献+

抗甲状腺药物治疗Graves病复发风险模型的构建与评估 被引量:1

Construction and evaluation of recurrence risk model of Graves′disease treated with antithyroid drugs
原文传递
导出
摘要 目的构建并评估抗甲状腺药物(ATD)治疗初发Graves病停药后复发风险预测模型。方法纳入2012年至2019年南京中医大学附属中西医结合医院内分泌科Graves病患者308例,ATD规范治疗后停药,据随访2年内是否复发进入复发组或缓解组,建立发现队列,bootstrap重抽样数据为验证队列。比较两组基线人口学特征、临床表现和Graves病相关检查指标。Cox回归筛选与Graves病复发相关危险因素并构建Graves病复发风险评估系统(GRES)预测模型。评价GRES模型预测效应并与Graves病治疗后复发事件评分(GREAT评分)模型进行比较。结果170例完成随访,90例停药2年内复发。Graves病家族史,年轻(<30岁),中重度甲状腺肿(Ⅱ度~Ⅲ度),高促甲状腺激素受体抗体(TRAb≥13 IU/L)水平,较大甲状腺体积(≥26.4 cm^(3))和低25羟维生素D水平[25(OH)D<14.7 ng/mL]6项因素进入预测模型:个体预后指数(PI)=0.672×家族史+0.405×年龄+0.491×甲状腺肿大程度+0.808×TRAb水平+1.423×甲状腺体积+0.579×25(OH)D水平。PI值≥1.449,停药后2年内复发风险较高。GRES模型评估Graves病患者停药后2年内是否复发的区分度与准确度均较好,且优于GREAT评分。结论本研究构建的GRES模型可用于评估初发Graves病患者停药后2年内的复发风险,指导临床医师根据预测的复发风险高低,合理选择治疗方案,提高缓解率。 Objective To establish and evaluate a predictive model for recurrence risk of Graves′disease after antithyroid drugs(ATD)withdrawal.Methods Among 308 patients with newly onset Graves′disease taking ATD from 2012 to 2019,170 patients who completed follow-up were enrolled and divided into relapse and remission groups according to whether hyperthyroidism reoccurred within 2 years after ATD withdrawal to establish the discovery cohort.An internal validation cohort was constructed by repeating the sampling with bootstrap.Cox regression analysis was used to screen risk factors and establish a predictive model,named Graves′Recurrence Evaluation System(GRES).The differentiation and accuracy of GRES model were evaluated and compared with the GREAT score.Results Of 170 patients,90 Graves′disease cases relapsed within 2 years after ATD withdrawal.According to Cox regression analysis,family history of Graves′disease,younger age(<30 years),gradeⅡ-Ⅲgoiter,high level of TRAb(≥13 IU/L),large thyroid volume(≥26.4 cm^(3))and low 25(OH)D(<14.7 ng/mL)were included in the predictive model:PI=0.672×family history+0.405×age+0.491×severity of goiter+0.808×TRAb+1.423×thyroid volume+0.579×25(OH)D.PI≥1.449 was associated with a higher risk of recurrence after drug withdrawal.The GRES model has good prediction in assessing Graves′disease relapse within 2 years after ATD withdrawal and better than GREAT score.Conclusion GRES model can be used to evaluate the recurrence risk within 2 years for patients with newly onset Graves′disease after ATD withdrawal,and facilitate clinicians to reasonably select treatment modalities in order to improve the remission rate.
作者 崔雯锦 徐书杭 胡欣 相萍萍 刘洲君 陈国芳 刘超 Cui Wenjin;Xu Shuhang;Hu Xin;Xiang Pingping;Liu Zhoujun;Chen Guofang;Liu Chao(Department of Endocrinology,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine Jiangsu Province Academy of Traditional Chinese Medicine,Nanjing 210028,China;Department of Endocrinology,Hospital of Nantong Haimen District of Traditional Chinese Medicine,Nantong 226100,China)
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2022年第5期382-390,共9页 Chinese Journal of Endocrinology and Metabolism
基金 国家自然科学基金(81904149) 国家中医药管理局重大疑难疾病中西医临床协作试点项目(2018) 江苏省六大人才高峰(WSN-035) 江苏省中医药领军人才(SLJ0209)。
关键词 抗甲状腺药物 格雷夫斯病 复发风险因素 预测模型 Antithyroid drugs Graves′disease Risk factors of recurrence Predictive model
  • 相关文献

参考文献4

二级参考文献19

  • 1白耀.甲状腺病学-基础与临床[M].北京:科学技术文献出版社,2004.388.
  • 2Davies TF, Larsen PR. Thyrotixicosis// Larsen PR, Kronenberg HM, Melmed S. Wlilliams textbook of endocrinology. 10th ed. Philadelphia: Saunders, 2002: 374-424.
  • 3Chiovato L, Babesino G, Pinchera A. Graves disease//DeGroot LJ, Jameson JL. Endocrinology. 4th ed. Philadelphia: Saunders, 2001 : 1422-1449.
  • 4Greenspan FS. The thyroid gland//Greenspan FS, Gardner DG. Basic and clinical endocrinology. New York: Lange /McGraw- Hill, 2001: 201-272.
  • 5Fisher DA. Disorders of the thyroid in the newborn and infant// Sperling MA. Pediatric endocrinology. 2nd ed. Philadelphia: Sannders, 2002 : 161-186.
  • 6Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med, 2000, 160:1573-1575.
  • 7American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract, 2002,8:457-469.
  • 8Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006, 354:2783-2793.
  • 9Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid, 2003,13 : 3-126.
  • 10Cooper DS. Antithyroid drugs. N Engl J Med, 2005, 352:905- 917.

共引文献859

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部